Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
RevitaT2Di Pivotal Study (REVITALIZE 1)
The Revitalize-1 Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the first layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This treatment may eliminate or reduce the need for insulin injections in the future for the treatment of Type 2 Diabetes.
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose.
ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not in normal tissue.
Study of SynKIR-110 Autologous T cells Transduced with Mesothelin KIR-CAR in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer Cholangiocarcinoma or Mesothelioma
This study involves research of an investigational therapy called SynKIR-110. SynKIR-110 is CAR T cell therapy. CAR T cell therapy is a type of treatment in which a patient’s T cells (white blood cells that are a part of the immune system) are changed in a laboratory so they can attack cancer cells. The purpose of this research study is to identify a safe dose of SynKIR-110 in patients with advanced Ovarian cancer, Cholangiocarcinoma (bile duct cancer) or Mesothelioma (a tumor of the tissue that lines the lungs, stomach, heart, and other organs).
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that
many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes
results when either the body does not make enough insulin or the body does not respond
correctly to this insulin, respectively. Insulin is a hormone which is made by cells in
the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the
body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar
to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D
patients. Currently, there is little understanding of CFRD and the best options for
treatment remain unclear.
The purpose of this research study is to examine and understand the various mechanisms
that contribute to CFRD and gain a better understanding of potential means to treat CFRD.
In particular, we plan to study the effects of incretin hormones that can enhance insulin
production in CF patients.
Enrollment is complete for the protocol as initially written. In order to further study
the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) function , we have received approval to extend our investigation to include the
following study groups:
Cystic Fibrosis participants with normal glucose tolerance Non-Cystic Fibrosis controls
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
